Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Ann Oncol 2012; 23: 2356–2362 (doi:10.1093/annonc/mdr620)

The following funding statement was missing from the original manuscript: ‘Supported by NIH grants U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology.’ This has now been amended in the online version.